13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001776382
Total reported value
$519.4M
$519.4M
6 檔
21.8%
At the close of Q2 2025, venBio Partners LLC disclosed equity holdings valued at approximately $519.4M, spread across 6 reported holdings.
In Q2 2025, venBio Partners LLC adopted a defensive or profit-taking posture, trimming 1 positions and completely liquidating 2 holdings to manage risk exposure.
In terms of portfolio concentration, the top 5 core holdings (including PHVS, HRMY, ALMS) accounted for 21.8% of total reported equity market value during Q2 2025.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | PHVS | Pharvaris N.V. | Stock-Other | 65.78% | -15.80% | — | |
| 2 | HRMY | Harmony Biosciences Holdings | Stock-Other | 13.47% | -1.57% | — | |
| 3 | ALMS | Alumis Inc | Stock-Other | 12.08% | -11.03% | +65.74% | |
| 4 | LYEL | Lyell Immunopharma Inc | Stock-Other | 3.65% | -1.50% | — | |
| 5 | ALXO | Alx Oncology Holdings Inc | Stock-Other | 3.51% | -4.07% | — | |
| 6 | ARTV | Artiva Biotherapeutics Inc | Stock-Other | 1.51% | -1.22% | EXIT |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | PHVS | Pharvaris N.V. | +11.3% | — | Unchanged |
| 2 | LYEL | Lyell Immunopharma Inc | +3.7% | NEW | New buy |
| 3 | HRMY | Harmony Biosciences Holdings | +0.3% | — | Unchanged |
| 4 | ALXO | Alx Oncology Holdings Inc | -1.4% | — | Unchanged |
| 5 | ARTV | Artiva Biotherapeutics Inc | -1.4% | -4.17% | Trim |
| 6 | ALMS | Alumis Inc | -1.8% | +65.74% | Add |
| 7 | LYEL | Lyell Immunopharma, Inc. | -3.1% | EXIT | Sold out |
| 8 | ✓ | Acelyrin Inc | -7.6% | EXIT | Sold out |
According to official SEC Form 13F filings, venBio Partners LLC reported a total U.S. public equity portfolio value of $519.4M across 6 disclosed positions in Q2 2025.
During Q2 2025, venBio Partners LLC's top holdings by market value included PHVS (65.8%)、HRMY (13.5%)、ALMS (12.1%). The largest single position, PHVS, represented 65.8% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Top New Position Initiated
LYEL
市值: $4.2M
Top Position Liquidated / Trimmed
ACELYRIN INC
前期市值: $9.4M
In Q2 2025, venBio Partners LLC made 5 total portfolio adjustments, initiating 1 new buys, adding to 1 positions, trimming 1 holdings, and fully liquidating 2 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.